

Electronic Acknowledgement Receipt

EFS ID:	5214195
Application Number:	09589288
International Application Number:	
Confirmation Number:	1519
Title of Invention:	METHODS OF INHIBITING B LYMPHOCYTES USING ANTIBODIES TO NEUTROKINE-ALPHA
First Named Inventor/Applicant Name:	Guo-Liang Yu
Customer Number:	73326
Filer:	John Jr. Kilyk/Himanshu Thakur
Filer Authorized By:	John Jr. Kilyk
Attorney Docket Number:	PF343P3C5
Receipt Date:	24-APR-2009
Filing Date:	08-JUN-2000
Time Stamp:	13:32:22
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Foreign Reference	EP1294769A2-1.pdf	22500420 273c74991977330ff0d7690816f463b4270be34db	no	350

Warnings:

Information:

2	Foreign Reference	EP1294769A2-2.pdf	10796595	no	350
			cd51c2e819160abf76184fe4c2525f5190184725		
Warnings:					
Information:					
3	Foreign Reference	EP1294769A2-3.pdf	8304449	no	350
			41c53cdabb5938336c28376e1467cb1ff3d931de		
Warnings:					
Information:					
4	Foreign Reference	EP1294769A2-4.pdf	8437707	no	350
			103ca22f1fbee3aa057bd080da1934c8232437f		
Warnings:					
Information:					
5	Foreign Reference	EP1294769A2-5.pdf	8429805	no	350
			3b4d56b3fbd57acde6a4abafe10f0853b3d6870d		
Warnings:					
Information:					
6	Foreign Reference	EP1294769A2-6.pdf	8416016	no	350
			72a580e0f6e4469e04fee6ddcd0d276fbd622ced		
Warnings:					
Information:					
7	Foreign Reference	EP1294769A2-7.pdf	8399822	no	350
			68d4426bab167ef6cda4e1eadf67c18187cd0abbb		
Warnings:					
Information:					
8	Foreign Reference	EP1294769A2-8.pdf	8336710	no	350
			520e0169c8f77242b6ca84a01ee346e4e5e74450		
Warnings:					
Information:					
9	Foreign Reference	EP1294769A2-9.pdf	7026114	no	348
			4dfc50a58f178ca19f2b5d4671ae116af0b7068f		
Warnings:					
Information:					
10	Foreign Reference	EP1456347A2-1.pdf	22309473	no	350
			fc004a04dcb67d52dde4e050c27324fb3a426e5		
Warnings:					
Information:					

11	Foreign Reference	EP1456347A2-2.pdf	10741054	no	350
			57a7be30fa76a066906a2e198a43a589007aa9d0		
Warnings:					
Information:					
12	Foreign Reference	EP1456347A2-3.pdf	8676887	no	350
			877cc6a1810a99b777d07e13932a58e3cc6be688		
Warnings:					
Information:					
13	Foreign Reference	EP1456347A2-4.pdf	8691683	no	350
			dbbfb47250f4c337bb4418db6d4265bfd50aac7		
Warnings:					
Information:					
14	Foreign Reference	EP1456347A2-5.pdf	8872298	no	350
			545957bb922182a2644d8469d799bb3465572765		
Warnings:					
Information:					
15	Foreign Reference	EP1456347A2-6.pdf	8872785	no	350
			7feef1c96a056948f14df5d1c505c1e72392db2		
Warnings:					
Information:					
16	Foreign Reference	EP1456347A2-7.pdf	8896942	no	350
			242133f3d19c965c4039ed80a89b2dda28dfb276		
Warnings:					
Information:					
17	Foreign Reference	EP1456347A2-8.pdf	15401974	no	649
			66af05daaf441e6e9f8c3994ae7c225d773c9705		
Warnings:					
Information:					
18	Foreign Reference	EP1507793A1-1.pdf	15702023	no	250
			b092d043dc7e297c55ac7893b9487d842d24efe8		
Warnings:					
Information:					
19	Foreign Reference	EP1507793A1-2.pdf	14634644	no	270
			d245e6aba84078a98bf1eb52c4cb9e9509b7695a		
Warnings:					
Information:					

20	Foreign Reference	EP1577391A1.pdf	799617	no	55
			8dad430ff4a1645180893b3a09e2d3b663944b4c		
Warnings:					
Information:					
21	Foreign Reference	EP1860190A2.pdf	3421776	no	247
			07dccf2573b13cf5414936ad0411af7555844c45		
Warnings:					
Information:					
22	NPL Documents	BiogenObservations-EP_1146892-2007.pdf	1878196	no	38
			8a3161abb5a772ea4654b0e9e8a7251004ab3e91		
Warnings:					
Information:					
23	NPL Documents	MelchersDeclaration-INT_105485-2006.pdf	1005734	no	22
			3dc2e9b032373e9456aac7af564a0f69cc029ebc		
Warnings:					
Information:					
24	NPL Documents	SchlisselDeclaration-INT_105485-2006.pdf	22033339	no	339
			9e7984843cfd0b2e11215a49691a089317fbec78		
Warnings:					
Information:					
25	NPL Documents	SchlisselSecondDeclaration-INT_105485-2007.pdf	217497	no	7
			aa5a63e6523a0ac451ad2c9e4f175457bc84deb4		
Warnings:					
Information:					
26	NPL Documents	SchlisselThirdDeclaration-INT_105485-2007.pdf	1022280	no	23
			12a1495c8c8ffbc7f65aebfe13bd92255dacf a31		
Warnings:					
Information:					
27	NPL Documents	NoelleDeclaration-INT_105485-2007.pdf	1968192	no	48
			171afdb4f55e8d508b6e6382c7754e63fbfe6fd7		
Warnings:					
Information:					
28	NPL Documents	SmithDeclaration-2004.pdf	6750607	no	87
			801af2f1861a03ffb3bb24c456a30aeb2fbcd b7a		
Warnings:					
Information:					

29	NPL Documents	SmithSecondDeclaration-2005.pdf	6321785	no	77
			a8cda2c87e936fa738823774a6f0c86c4cd9cd73		
Warnings:					
Information:					
30	NPL Documents	MelchersDeclaration-EP_1146892-2007.pdf	1113442	no	25
			0fb09eb0f2b558eb98c28c02030c5527b1a862f0		
Warnings:					
Information:					
31	NPL Documents	WareDeclaration-INT_105485-2007.pdf	919652	no	22
			decf5f90b40ffc3a77290190729f11adf8b55d24		
Warnings:					
Information:					
32	NPL Documents	GehaDeclaration-INT_105485-2007.pdf	1126934	no	26
			7ea1c32fd74ea5bbfb263dad38fed712d93997f6		
Warnings:					
Information:					
33	NPL Documents	DeclarationofInterference-INT_105485.pdf	335402	no	8
			636ff240489429b42703a2781a6ba851eae35d9e		
Warnings:					
Information:					
34	NPL Documents	GenbankAccessionNo-P01374.pdf	69182	no	8
			657f4cdd29cb3ddb50b620aa51b290d57eba8fe6		
Warnings:					
Information:					
35	NPL Documents	GenbankAccessionNo-CAA25649.pdf	53420	no	2
			9833867324d6b6faaf95199036a7182415d28fc7		
Warnings:					
Information:					
36	NPL Documents	HGSBackgrounder-BLymphocyteStimulator-2000.pdf	31082	no	1
			f83c4ce20b67ac0dba7074027bc22ad8cf1b8038		
Warnings:					
Information:					
37	NPL Documents	HGSBackgrounder-SystemicLupusErythematosus-2000.pdf	97293	no	2
			b6aa7841288c76fc1dad3f1ca23ace30cc9624cd		
Warnings:					
Information:					

38	NPL Documents	HGSSackgrounder- ImmunoglobulinADeficiency-2 001.pdf	176584	no	3
			117b5d084c832d95c36a542e4401ab779be92a73		
Warnings:					
Information:					
39	NPL Documents	HGSPressRelease- HGSDiscoveryNovellImmuneSti mulant-1999.pdf	215221	no	3
			318ba92144fb8c4f9027ad81a328fb3d4a1263dd		
Warnings:					
Information:					
40	NPL Documents	HGSPressRelease- HGSAvanceHodgkinsLympho ma-1999.pdf	186393	no	3
			a4b09f80c78afb5d45af8afe9b6a988dd2e5542b		
Warnings:					
Information:					
41	NPL Documents	HGSPressRelease- NewAntiAngiogenicProteins-19 99.pdf	193626	no	3
			8cd7b177150f6043ede266e20115c2038163956d		
Warnings:					
Information:					
42	NPL Documents	HGSPressRelease- HGSReports1999FinancialResul ts-2000.pdf	335734	no	6
			f0d5507ff5464e6971bf79093af538164f865215		
Warnings:					
Information:					
43	NPL Documents	HGSPressRelease- HGSReports1stQYFinancialResu lts-2000.pdf	273258	no	6
			08e85acab9528bd65647ae94b52a19cf8fbcd1d29		
Warnings:					
Information:					
44	NPL Documents	HGSPressRelease- HGSandCATAntiBlysAntibodies -2000.pdf	192488	no	3
			6243302d155a7168ba74e019c93fa86d0a679835		
Warnings:					
Information:					
45	NPL Documents	HGSPressRelease- HighLevelsBlysLupusRheumato idArthritis-2000.pdf	169663	no	3
			7e3907efbdc527e7b598fe2278360033b1133c17		
Warnings:					
Information:					
46	NPL Documents	HGSPressRelease- HGSandDOWRadioBlys-2000. pdf	162481	no	2
			7aa210c36de5fa7143bf295ec23cd085c30bde72		
Warnings:					
Information:					

47	NPL Documents	HGSPressRelease-HGSReportsFinancialResults4th QY-2001.pdf	448290	no	7
			798e6be016c728c0bc797f9bf74fd574abe12a7f		
Warnings:					
Information:					
48	NPL Documents	HGSPressRelease-HGSAntibodyMfgFacility-2001.pdf	143577	no	2
			5ab6d7f5883d935d1b658d35b8dd6e32cb47cbba		
Warnings:					
Information:					
49	NPL Documents	HGSPressRelease-HGSOrphanDrugDesignation-2001.pdf	154201	no	2
			6cd4be86e1caf0efbca294dcb9d02762efa54889		
Warnings:					
Information:					
50	NPL Documents	HGSPressRelease-HGSLargeScaleMfgPlant-2001.pdf	125933	no	2
			0fc9a130ef503294ff8623db3cf87cb5422b0191		
Warnings:					
Information:					
51	NPL Documents	HGSPressRelease-HGSTrialSystemicLupusErythematosus-2001.pdf	1010845	no	18
			9f9fbc9304beba3b5a998d96dd275a31c035c5ff		
Warnings:					
Information:					
52	NPL Documents	HGSPressRelease-HGSDataSupportPotentialLymphostatB-2001.pdf	17618	no	2
			af4a159bc8bb52823eb3359c9a3362a06a848fcc		
Warnings:					
Information:					
53	NPL Documents	HGSPressRelease-HGSDataAmericanSocietyHematologyMeeting-2001.pdf	185567	no	3
			4a9ac0ccfce218735d2cab6842595b424081bfa2		
Warnings:					
Information:					
54	NPL Documents	HGSPressRelease-HGSInvestigationalDrugLymphorad131-2002.pdf	174073	no	2
			0498a99fd00badb9f5a85d589bf6de64a85ecaf1		
Warnings:					
Information:					
55	NPL Documents	HGSPressRelease-HGSReports2001FinancialResults-2002.pdf	451937	no	7
			29f1030552ffc6923e702d882e7246fa4f242536		
Warnings:					
Information:					

56	NPL Documents	HGSPressRelease-HGSProvidesUpdateCompanyProgress-2002.pdf	650887 ff226848db7404672584afb343780d8a28e0e0d	no	8
Warnings:					
Information:					
57	NPL Documents	HGSPressRelease-HGSAnnouncesClearanceDrugApplicationLymphorad131-2002.pdf	218612 517e24b1c3422fa9301f6a7f32a266798b1b3594	no	3
Warnings:					
Information:					
58	NPL Documents	HGSPressRelease-HGSActivityCancerDrugAmericanSocietyClinicalOncology-2002.pdf	190748 a71eae32c3c320404013132dc0ec9eda146b7c6	no	3
Warnings:					
Information:					
59	NPL Documents	HGSPressRelease-HGSandCATDevelopmentAntibodyTrialReceptor2-2002.pdf	181975 6d096892175d5163c077c363ceb26b8a233863d2	no	3
Warnings:					
Information:					
60	NPL Documents	HGSPressRelease-HGS2ndQY2002FinancialResults-2002.pdf	144471 c1693a95b3a84e4fe17a9b1d3083b3e6fd60f4da	no	3
Warnings:					
Information:					
Total Files Size (in bytes):			268617013		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					